

RFQ/RFP: 500 mg AZ pills and placebo pills (released December 14, 2018)

Questions and Answers

Please note: Responses to questions or comments not included below are addressed in the updates to the RFP.

1. Question: Is there any breakdown per quantity and per destination?

Answer: We anticipate that the pills will be distributed in approximately equal quantities across each of the eight sites noted on pg. 2 of the RFQ/RFP (Pakistan [Karachi], India location 1 [Nagpur], India location 2 [Belagavi], Kenya [Nairobi], Democratic Republic of Congo [Kinshasa], Zambia [Lusaka], Guatemala [Guatemala City], and Bangladesh [Dhaka]). This equates to approximately 10,000 azithromycin pills and 10,000 placebo pills per site.

2. Question: What would be the minimum and maximum quantity requested on a PO for a shipment to a single destination?

Answer: We anticipate that there will be at least 2 shipments to each site. For the first shipment, equal quantities will be sent to each site. For the second or any subsequent shipments, the amount shipped to each site may be adjusted depending on enrollment rates.

3. Question: Would you also accept 3 tablet blister packs instead of 4 tablet blister packs?

Answer: Each dose must contain a 2 g of Azithromycin or identically packaged placebo. Our suggested packaging is four 500 mg azithromycin pills (or identical placebo) per blister pack; however, we would accept two 1g dose blister packs, with each blister pack containing 2 individual 500 mg pills.

4. Question: Please detail the randomization labeling requirement: is this a label to be placed on the primary, secondary or tertiary packaging?

Answer: The randomization label will be placed on the primary packaging (corresponding to each study dose of 2g azithromycin or placebo).

5. Question: Can you kindly confirm that you want a total of: 320,000 tablets (80,000 packs of 4 tablets)?

Answer: Incorrect, the total quantity of pills needed is 80,000 tablets for each of azithromycin and placebo (a total of 160,000 tablets), as indicated in the revised RFP.

6. Question: Do you want us to provide transportation quote to the research sites in the following countries: Pakistan (Karachi), India location 1 (Nagpur), India location 2 (Belagavi), Kenya (Nairobi), Democratic Republic of Congo (Kinshasa), Zambia (Lusaka), Guatemala (Guatemala City), and Bangladesh (Dhaka)?

Answer: If you decide to submit a quote for transportation costs, please leave the transportation portion out of the quote. RTI will handle the shipping and logistics, as indicated in the revised RFP.

- 7. Question: If we need any clarification about the work to be performed, who should we address our inquiries?**
- 8.**

Answer: Inquiries should be addressed to Mohamed Jallow (mjallow@rti.org), Senior Supply Chain Specialist, RTI International.

- 9. Question:** Which is the solicitation number? Is it SSES-PHS-FY15-001?

Answer: Yes, it is SSES-PHS-FY15-001.

- 10. Question:** In the product expectations (first page of Attachment A), paragraph 4, it indicates that the product has to be packaged in boxes with randomization number. Do you mean a box including one blister?

Answer: We have updated the RFP to clarify the expectations for packaging and labeling. The bidder is expected to label the individual blister packs with a unique randomization ID based on the randomization scheme provided by RTI International and then packaged sequentially into boxes for shipment. The randomization labeling is not required on the shipping boxes.

- 11. Question:** How should fixed costs that are not proportional per unit be applied?

Answer: Given the number of pills to be purchased is determined (80,000 Azithromycin and 80,000 placebo), please include fixed costs in the unit cost.

- 12. Question:** Will advanced payments be made?

Answer: If an advanced payment is required, the bidder should include this assumption in the proposal.